Krystal Biotech (KRYS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the stock and has a $202.00 price target.
Ritu Baral has given her Buy rating due to a combination of factors that highlight Krystal Biotech’s potential for growth despite recent challenges. The company’s Vyjuvek sales were below expectations, primarily due to compliance issues, slow initiation of new patients, and plan switching. However, Krystal Biotech is taking proactive steps to address these challenges by planning to expand its U.S. sales force by approximately 50%, which is expected to enhance physician and patient education and drive future sales growth.
Moreover, the company has shown a strong demand for its product, with over 540 patient reimbursement approvals secured, indicating a solid market presence. Despite the current revenue miss, the company’s strategic initiatives and the potential for future revenue growth underpin Ritu Baral’s Buy rating. The financial stability, as evidenced by a substantial cash reserve, and maintained operational expenditure guidance further support the positive outlook for Krystal Biotech’s stock.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $240.00 price target.